Octreotide LAR for the treatment of acromegaly

Bibliography

• Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9
   PubMed Web of Science ®Google Scholar
• McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003;63:2473-99
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2007; [Epub ahead of print]
   PubMedGoogle Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355:2558-73
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41
   PubMedGoogle Scholar
• Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613-9
   PubMed Web of Science ®Google Scholar
• Ritchie CM, Atkinson AB, Kennedy AL, et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 1990;59:55-62
   PubMedGoogle Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-7
   PubMed Web of Science ®Google Scholar
• Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102
   PubMed Web of Science ®Google Scholar
• Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 2007;92:4271-7
   PubMed Web of Science ®Google Scholar
• Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991;115:527-32
   PubMed Web of Science ®Google Scholar
• Burt MG, Ho KK. Newer options in the management of acromegaly. Intern Med J 2006;36:437-44
   PubMed Web of Science ®Google Scholar
• Serri O, Somma M, Comtois R, et al. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 1985;61:1185-9
   PubMed Web of Science ®Google Scholar
• Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Rev Endocr Metab Disord 2008;9:67-70
   PubMed Web of Science ®Google Scholar
• Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-91
   PubMed Web of Science ®Google Scholar
• Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005;62:210-6
   PubMed Web of Science ®Google Scholar
• Castinetti F, Morange I, Dufour H, et al. Radiotherapy and radiosurgery in acromegaly. Pituitary 2008; [Epub ahead of print]
   Google Scholar
• Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613-7
   PubMed Web of Science ®Google Scholar
• Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90:4483-8
   PubMed Web of Science ®Google Scholar
• Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003;88:3105-12
   PubMed Web of Science ®Google Scholar
• Mandarino L, Stenner D, Blanchard W, et al. Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature 1981;291:76-7
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-42
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98
   PubMed Web of Science ®Google Scholar
• Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-67
   PubMed Web of Science ®Google Scholar
• Lania A, Mantovani G, Spada A. Genetic abnormalities of somatostatin receptors in pituitary tumors. Mol Cell Endocrinol 2007
   PubMedGoogle Scholar
• Hu C, Yi C, Hao Z, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004;3:726-30
   PubMed Web of Science ®Google Scholar
• Bousquet C, Puente E, Buscail L, et al. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001;47(Suppl 2):30-9
   PubMed Web of Science ®Google Scholar
• Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984;59:1148-51
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Guillen S, et al. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006;83:258-63
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140-5
   PubMed Web of Science ®Google Scholar
• Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996;45:27-30
   PubMed Web of Science ®Google Scholar
• Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99
   PubMed Web of Science ®Google Scholar
• Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-72
   PubMed Web of Science ®Google Scholar
• Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-7
   PubMed Web of Science ®Google Scholar
• Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311-6
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090-8
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9
   PubMed Web of Science ®Google Scholar
• Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86-91
   PubMed Web of Science ®Google Scholar
• Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89:658-61
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-73
   PubMed Web of Science ®Google Scholar
• Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005;90:6290-5
   PubMed Web of Science ®Google Scholar
• Barlier A, Pellegrini-Bouiller I, Gunz G, et al. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999;84:2759-65
   PubMed Web of Science ®Google Scholar
• Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001;86:3809-14
   PubMed Web of Science ®Google Scholar
• Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999;1:105-14
   PubMedGoogle Scholar
• Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006;64:342-51
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-86
   PubMed Web of Science ®Google Scholar
• Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001;55:477-83
   PubMed Web of Science ®Google Scholar
• Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004;151:309-15
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003;58:169-76
   PubMed Web of Science ®Google Scholar
• Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) 2006;65:626-30
   PubMed Web of Science ®Google Scholar
• Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-63
   PubMed Web of Science ®Google Scholar
• Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
   PubMed Web of Science ®Google Scholar
• Casarini AP, Pinto EM, Jallad RS, et al. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 2006;29:826-30
   PubMed Web of Science ®Google Scholar
• Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007;92:1592-9
   PubMed Web of Science ®Google Scholar
• Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034-40
   PubMed Web of Science ®Google Scholar
• Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002;56:65-71
   PubMed Web of Science ®Google Scholar
• Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-63
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66:859-68
   PubMed Web of Science ®Google Scholar
• Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-I hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67:282-9
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Akker S, Chew SL, et al. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000;53:719-24
   PubMed Web of Science ®Google Scholar
• Stewart PM, Stewart SE, Clark PM, Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 1999;50:295-9
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 2008;158:19-25
   PubMed Web of Science ®Google Scholar
• Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996;45:72-4
   PubMed Web of Science ®Google Scholar
• Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001;145:137-45
   PubMed Web of Science ®Google Scholar
• Stevenaert A, Beckers A. Presurgical octreotide treatment in acromegaly. Acta Endocrinol (Copenh) 1993;129(Suppl 1):18-20
   PubMedGoogle Scholar
• Losa M, Mortini P, Urbaz L, et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006;104:899-906
   PubMed Web of Science ®Google Scholar
• Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 2005;147:485-93
   PubMed Web of Science ®Google Scholar
• Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6
   PubMed Web of Science ®Google Scholar
• Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150:473-80
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150:489-95
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007;67:512-9
   PubMed Web of Science ®Google Scholar
• Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2007
   PubMedGoogle Scholar
• Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8
   PubMed Web of Science ®Google Scholar
• Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-15
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Kopchick JJ. Growth hormone receptor antagonists. Neuroendocrinology 2006;83:264-8
   PubMed Web of Science ®Google Scholar
• Strasburger CJ, Buchfelder M, Droste M, et al. Experience from the German pegvisomant observational study. Horm Res 2007;68(Suppl 5):70-3
   PubMedGoogle Scholar
• Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-6
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006;91:121-8
   PubMed Web of Science ®Google Scholar
• Novartis, octreotide LAR. Available from: http://www.rxlist.com
   Google Scholar
• Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008;37:101-22, viii
   PubMed Web of Science ®Google Scholar
• Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135-41
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Melmed S. Pasireotide: a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 2007;10:885-95
   PubMed Web of Science ®Google Scholar
• Emery PT, Higgs NB, Warhurst AC, et al. Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with P-glycoprotein. Br J Pharmacol 2002;135:1443-8
   PubMed Web of Science ®Google Scholar
• Available from: www.chemblink.com/structures/51110-01-1.gif
   Google Scholar